417 related articles for article (PubMed ID: 34757064)
21. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
22. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
24. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.
Walti CS; Krantz EM; Maalouf J; Boonyaratanakornkit J; Keane-Candib J; Joncas-Schronce L; Stevens-Ayers T; Dasgupta S; Taylor JJ; Hirayama AV; Bar M; Gardner RA; Cowan AJ; Green DJ; Boeckh MJ; Maloney DG; Turtle CJ; Hill JA
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33914708
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Kallam A; Vose JM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
27. Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.
Chakraborty R; Hill BT; Majeed A; Majhail NS
Transplant Cell Ther; 2021 Mar; 27(3):222-229. PubMed ID: 33928266
[TBL] [Abstract][Full Text] [Related]
28. [Management of adverse effects in CAR T-cell therapy].
Goto H
Rinsho Ketsueki; 2023; 64(9):1203-1212. PubMed ID: 37899201
[TBL] [Abstract][Full Text] [Related]
29. Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T-cells (CAR-T): A comprehensive review on incidence, risk factors and current management.
Galli E; Fresa A; Bellesi S; Metafuni E; Maiolo E; Pansini I; Frioni F; Autore F; Limongiello MA; Innocenti I; Giammarco S; Chiusolo P; Zini G; Sorà F
Eur J Haematol; 2024 Feb; 112(2):184-196. PubMed ID: 37491951
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
32. Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia.
Ceppi F; Gardner RA
Cancer J; 2019; 25(3):191-198. PubMed ID: 31135526
[TBL] [Abstract][Full Text] [Related]
33. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
[TBL] [Abstract][Full Text] [Related]
34. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
35. Clinical experience of CAR T cell therapy in lymphomas.
Oluwole OO
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101281. PubMed ID: 34625227
[TBL] [Abstract][Full Text] [Related]
36. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
37. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
Meir J; Abid MA; Abid MB
Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
[TBL] [Abstract][Full Text] [Related]
38. Prolonged haematologic toxicity in CAR-T-cell therapy: A review.
Liu Q; Hu T; Li H; Shen Y; Wu D; Ye B
J Cell Mol Med; 2023 Dec; 27(23):3662-3671. PubMed ID: 37702530
[TBL] [Abstract][Full Text] [Related]
39. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
Sun W; Liang AB; Huang H; Huang XJ
Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
[TBL] [Abstract][Full Text] [Related]
40. Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
Chodnicki KD; Prasad S
Semin Ophthalmol; 2021 May; 36(4):329-334. PubMed ID: 33689570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
